

**Amendments to the Claims:**

Please amend claims 1, 2, 19, 26, 53, 54 and 56 and cancel claims 5, 3-18, 20-25, 27-52 and 57-80 without prejudice.

This listing of claims will replace all prior versions, and listings, of claims in the application.

**In the Claims:**

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises:

a) a therapeutically effective amount of an ~~ECM-binding~~ extracellular matrix-binding fragment of Ang-1 protein that ~~comprises selected from the group consisting of~~ SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 ~~and/or and~~ SEQ ID NO:4, ~~or a homologous peptide thereof~~ and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes an ~~ECM-binding~~ extracellular matrix-binding fragment of Ang-1 protein that ~~comprises selected from the group consisting of~~ SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 ~~and/or and~~ SEQ ID NO:4, ~~or a homologous peptide thereof;~~

b) ~~a therapeutically effective amount of a non-ECM binding fragment of Ang-1 protein that comprises a modification in an ECM binding domain of Ang-1, wherein said modification reduces the binding of Ang-1 to an extracellular matrix (ECM) and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a non-ECM binding fragment of Ang-1 protein that comprises a modification in an ECM binding domain of Ang-1, wherein said modification reduces the binding of Ang-1 to the (ECM); or~~

e) ~~a therapeutically effective amount of a proteolytic resistant fragment of Ang-1 protein that comprises a modification in a proteolytic domain of Ang-1, wherein said modification inhibits the proteolysis of Ang-1 and/or a vector comprising a nucleic acid~~

~~molecule that comprises the nucleotide sequence that encodes a proteolytic resistant fragment of Ang-1 protein that comprises a modification in a proteolytic domain of Ang-1, wherein said modification inhibits the proteolysis of Ang-1.~~

2. (Currently amended) The pharmaceutical composition of claim 1 comprising a therapeutically effective amount of an ~~ECM-binding~~ extracellular matrix-binding fragment of Ang-1 protein selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 ~~and/or~~ and SEQ ID NO:4.

3-18. (Canceled)

19. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 ~~which retain their~~ having angiogenesis promoting activity but which have reduced or inactive ~~ECM-binding extracellular matrix-binding~~ or a homologous peptide thereof or mutant versions of Ang-1 or a homologous peptide thereof and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a mutant Ang-1 which retain their angiogenesis promoting activity but which have reduced or inactive ECM-binding or a homologous peptide thereof or mutant versions of Ang-1.

20-25. (Canceled)

26. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 ~~which retain their~~ having angiogenesis promoting activity but which is not cleaved into a antagonist fragment, ~~or a~~

~~homologous peptide thereof or a homologous peptide thereof or and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that a mutant Ang-1 which retain their angiogenesis promoting activity but which has is not cleaved into a antagonist fragment or a homologous peptide thereof.~~

27-52. (Canceled)

53. (Currently amended) A pharmaceutical composition comprising

- a) a pharmaceutically acceptable carrier and
  - b) a therapeutically effective amount of an Ang-1 fragment with antagonist activity,
- ~~and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of an Ang-1 fragment with antagonist activity.~~

54. (Currently amended) The pharmaceutical composition of claim 53 further comprising Ang-2 protein, ~~and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of Ang-2.~~

55. (Original) The pharmaceutical composition of claim 53 comprising a therapeutically effective amount of an Ang-1 fragment with antagonist activity.

56. (Currently amended) The pharmaceutical composition of claim 53 wherein said Ang-1 fragment with antagonist activity comprises an amino acid sequence comprising SEQ ID NO:11 and/or SEQ ID NO:12, ~~and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence encoding for SEQ ID NO:29 and/or SEQ ID NO:30.~~

57-80. (Canceled)